Novartis will officially spin its Alcon eye-care business off into a separately traded standalone business unit on April 9, 2019.
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.
Novartis’ eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit 2019.
Switzerland-based Novartis announced plans to spin off Alcon, its eye care division, into a separately traded standalone company.
The Bill & Melinda Gates Foundation spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston.
Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.
Johnson & Johnson today announced the completion of the acquisition of Actelion Ltd. for a total purchase price of approximately $30 billion in cash.
Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.
Celgene will acquire Acetylon Pharmaceuticals and spin off some of its pipeline into a new company, Regenacy Pharmaceuticals.
After the announcement by Biogen that it was spinning off its hemophilia business, analysts and investors are pondering, somewhat quizzically, just what it means.